Search Results - Tim Bancroft
- Showing 1 - 5 results of 5
-
1
Evaluation of adverse clinical outcomes in patients with inflammatory bowel disease receiving different sequences of first- and second-line biologic treatments: findings from ROTAR... by Noa Krugliak Cleveland, Sabyasachi Ghosh, Benjamin Chastek, Tim Bancroft, Ninfa Candela, Tao Fan, Kandavadivu Umashankar, David T. Rubin
Published in BMC Gastroenterology (2024-09-01)Get full text
Article -
2
Gaps in hepatocellular carcinoma surveillance among insured patients with hepatitis B infection without cirrhosis in the United States by Mindie H. Nguyen, Lewis R. Roberts, Nicole M. Engel‐Nitz, Tim Bancroft, A. Burak Ozbay, Amit G. Singal
Published in Hepatology Communications (2022-12-01)Get full text
Article -
3
Relative vaccine effectiveness of MF59-adjuvanted vs high-dose trivalent inactivated influenza vaccines for prevention of test-confirmed influenza hospitalizations during the 2017–... by Ian McGovern, Benjamin Chastek, Tim Bancroft, Noah Webb, Mahrukh Imran, Stephen I. Pelton, Mendel D.M. Haag
Published in International Journal of Infectious Diseases (2024-09-01)Get full text
Article -
4
Comparable effectiveness of MF59®-adjuvanted and high-dose quadrivalent inactivated influenza vaccines for prevention of test-confirmed influenza during the 2022-2023 influenza sea... by Mahrukh Imran, Benjamin Chastek, Tim Bancroft, Noah Webb, Stephen I. Pelton, Mendel D.M. Haag, Ian McGovern
Published in International Journal of Infectious Diseases (2025-10-01)Get full text
Article -
5
Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory... by Alexander Russell-Smith, Louise Murphy, Amy Nguyen, Cori Blauer-Peterson, Marilou Terpenning, Feng Cao, Shiqiang Li, Tim Bancroft, Noah Webb, Stephanie Dorman, Richa Shah
Published in Journal of Comparative Effectiveness Research (2023-12-01)Article